Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7728845 | 1.00 | BDKRB2 (0.41) | BDKRB2MAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL21436252 | 1.00 | BDKRB2 (0.41) | BDKRB2MAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL21436267 | 1.00 | BDKRB2 (0.41) | BDKRB2MAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7727989 | 1.00 | BDKRB2 (0.41) | BDKRB2MAPTRAB9ASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL7728600 | 0.99 | HDAC1 (0.42) | BDKRB2MAPTRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL21523168 | 0.91 | BDKRB2 (0.37) | BDKRB2HDAC1HDAC4HDAC3HDAC7 | |
| SCHEMBL7726703 | 0.91 | BDKRB2 (0.37) | BDKRB2HDAC1HDAC4HDAC3HDAC7 | |
| SCHEMBL21436298 | 0.91 | F2 (0.36) | BDKRB2HDAC1HDAC4NFKB1NFKB2 | |
| SCHEMBL7734240 | 0.91 | F2 (0.36) | BDKRB2HDAC1HDAC4NFKB1NFKB2 | |
| SCHEMBL7734119 | 0.91 | BDKRB2 (0.41) | BDKRB2MAPTRAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | RHODE ISLAND HOSPITAL (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-05-13 | — | — | US | disclosed |
| EP-3773602-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-02-17 | — | — | EP | disclosed |
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | RHODE ISLAND HOSPITAL | 2020-08-27 | — | — | US | disclosed |
| US-20190328687-A1 | Antibacterial Compounds | VICTORIA LINK LIMITED (NZ) | 2019-10-31 | — | — | US | disclosed |
| WO-2019192968-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2019-10-10 | — | — | WO | disclosed |
| EP-3220919-A1 | ANTIBACTERIAL COMPOUNDS | Victoria Link Limited (NZ) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016080846-A1 | ANTIBACTERIAL COMPOUNDS | COPP JANINE NAOMI (NZ) | 2016-05-26 | — | — | WO | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | MALT1, SI, BCL6 | BDKRB2 3681/4885MAPT 4827/4885RAB9A 2128/4885 |
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | MALT1, SI, BCL6 | BDKRB2 3681/4885MAPT 4827/4885RAB9A 2128/4885 |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | MGLL, NIT2, SI | BDKRB2 3033/4885MAPT 4714/4885RAB9A 2017/4885 |
| US-20190328687-A1 | Antibacterial Compounds | SHARPIN, FDPS, BROX | BDKRB2 3379/4885MAPT 3628/4885RAB9A 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.